MKB Biopharma
MKB Biopharma is a life science consortium dedicated to investing, acquiring, and partnering with SMEs in the biotech and pharmaceutical industries. Their mission is to accelerate the discovery, development, and production of life-saving drugs and devices through innovative processes, advanced technologies, and strategic collaborations. They focus on biologics and medical devices, emphasizing quality, safety, and efficiency, with a strong leadership team experienced in biotech operations, finance, and strategic growth. The company aims to build an ecosystem that fosters innovation, scalability, and sustainable growth, ultimately improving patient outcomes and expanding access to advanced therapies.
Industries
Nr. of Employees
small (1-50)
MKB Biopharma
Bedford, Bedfordshire, United Kingdom, Europe
Services
Providing capital, acquiring or investing in life-science SMEs and integrating them into a shared-services ecosystem to scale operations.
Standardizing procedures and providing shared operational services (supply chain, logistics, quality systems) to improve efficiency and reduce lead times.
Provision of AI/ML-driven data analysis, virtual screening, target identification, disease modeling and precision-medicine analytics as outsourced services.
Contract or integrated manufacturing support including single-use processing, aseptic manufacturing practices, downstream purification and scale-up support.
Advisory and implementation support for GMP/GLP/ISO compliance, QbD, process validation, QA/QC systems and auditing; includes data protection measures for outsourced work.
Community and network access for portfolio companies to industry experts, shared technologies and market opportunities.
Providing capital, acquiring or investing in life-science SMEs and integrating them into a shared-services ecosystem to scale operations.
Standardizing procedures and providing shared operational services (supply chain, logistics, quality systems) to improve efficiency and reduce lead times.
Provision of AI/ML-driven data analysis, virtual screening, target identification, disease modeling and precision-medicine analytics as outsourced services.
Contract or integrated manufacturing support including single-use processing, aseptic manufacturing practices, downstream purification and scale-up support.
Advisory and implementation support for GMP/GLP/ISO compliance, QbD, process validation, QA/QC systems and auditing; includes data protection measures for outsourced work.
Community and network access for portfolio companies to industry experts, shared technologies and market opportunities.
Expertise Areas
- Biologics manufacturing and scale-up
- Medical device (Class III) manufacturing
- CDMO and contract manufacturing support
- Process optimization and supply chain
Key Technologies
- Single-use disposable bioreactors
- Disposable bioprocessing systems
- Membrane-based chromatography
- Resin-based chromatography
News & Updates
Biologics are a rapidly growing segment of the pharmaceutical industry, with opportunities to improve manufacturing efficiency and reduce costs through technological advances.
Manufacturing biologics involves complex processes and strict regulatory requirements. The article discusses the challenges and innovative strategies to overcome them.
Bioscience and AI outsourcing services are accelerating biotech research, enabling faster discoveries, and improving drug development processes.
The article explores the future landscape of Contract Development and Manufacturing Organizations (CDMOs) post-pandemic.
Biologics are transforming healthcare with innovative treatments. Advances in manufacturing technology are key to making these therapies more accessible and affordable.
Manufacturing biologics presents unique challenges due to their complex nature. Overcoming these hurdles requires innovative solutions and advanced technologies.
Biologics are a rapidly growing segment of the pharmaceutical industry, with opportunities to improve manufacturing efficiency and reduce costs through technological advances.
Manufacturing biologics involves complex processes and strict regulatory requirements. The article discusses the challenges and innovative strategies to overcome them.
Bioscience and AI outsourcing services are accelerating biotech research, enabling faster discoveries, and improving drug development processes.
The article explores the future landscape of Contract Development and Manufacturing Organizations (CDMOs) post-pandemic.
Biologics are transforming healthcare with innovative treatments. Advances in manufacturing technology are key to making these therapies more accessible and affordable.
Manufacturing biologics presents unique challenges due to their complex nature. Overcoming these hurdles requires innovative solutions and advanced technologies.